December 1, 2009 - Cedar Knolls, NJ -- Xybion Acquires Amadeus, a Leader in Governance, Risk, Compliance and Quality Management (GRC) Solutions
Amadeus will operate as a division of Xybion Corporation.
Xybion Corporation announced today that it has completed the acquisition of all operating assets of Quebec City based Amadeus Solutions, a leader in the development of enterprise governance, risk, compliance and quality management software solutions, from DECIMAL, a corporate performance management organization headquartered in Montreal.
Amadeus has been partnering with organizations in life sciences, manufacturing, finance and government sectors to manage risk, quality and compliance by automating processes such as corrective and preventive actions, non-conformance and defects, complaints management, audits, training, SOP management, incident management, programs and project management, vendor management, document management and corporate governance and other related quality and business processes. The Amadeus’s eQCM® web-based software platform enables organizations to comply with requirements stemming from FDA, ISO and other regulatory standards (like GxP, FDA 21 CFR Part 11, ISO 9001, ISO14001), financial reporting and governance regulations (Sarbanes-Oxley and Canada Bill 198), and other industry standards and risk-based regulations. Designed for maximum flexibility and easy adaptation to an organizations unique Governance, Compliance & Risk management (GRC) processes, eQCM® is coupled with powerful business intelligence capabilities, enterprise content management , and related technologies that help organizations achieve sustained compliance and improve process performance.
| "Amadeus further strengthens our holistic strategic approach to delivering enterprise solutions to our life science and medical research partners" |
“Initially, we were searching for a partner to help to expand our penetration of the US and European life sciences market with the Amadeus solutions,” remarked Stéphane Gaouette, president of DECIMAL, “During our time of reviewing each other’s capabilities and core competencies, it became evident that Xybion should take a leading role in moving the Amadeus products and services forward.”
While Amadeus will be a wholly owned division of Xybion Corporation, DECIMAL will retain a position on the board of directors of Amadeus business to continue to provide guidance and insight for product and market growth. DECIMAL will also be a partner with Xybion, retaining exclusive rights in Quebec for distribution of Amadeus’ Internal Controls Management (ICM) product.
All of the employees of Amadeus have been retained by Xybion. The Quebec City office will function as Xybion’s Center of Excellence for the GRC business.
About Xybion:
Xybion is the enterprise system partner of choice for life sciences product companies and research organizations worldwide for end-to end needs in the pre-clinical R&D, Quality, Regulatory risk and compliance management solutions. In addition to Pristima™, and Pristima™ VM, Providence®, eQRP®, eQCM®, Xybion provides professional services, consulting, training and validation activities to clients around the world. (www.xybion.com).
About Amadeus:
Amadeus, a division of Xybion, is a leading provider of Enterprise Quality and Compliance Management software solutions. For over 14 years, customers in the Life Sciences, Manufacturing, Financial Services and other industries have automated their compliance and quality processes using Amadeus software platforms. Its flagship product, eQCM, offers an integrated and very cost effective solution for enterprise governance, risk management, quality and compliance management. Amadeus’s solutions have been implemented in more than 100 companies in North America and Europe. (www.amadeussolutions.com)
About DECIMAL:
DECIMAL, the leader in corporate performance management (CPM) and in governance, risk, and compliance management (GRC), provides private, public and paragovernmental organizations, for nearly twenty years, with consulting services and software solutions. DECIMAL improves corporate performance by providing all decision-makers with all required financial information to better understand their costs, their profitability, optimize their budget and provide sound governance. (www.decimal.ca)
November 9, 2009 - Cedar Knolls, NJ -- Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management
Product release is a research industry first, allowing veterinary research subjects, research facilities and research safety study data to be managed in one software application.
Xybion Medical Systems announced today that it has unveiled Pristima™ VM, an integrated enterprise software solution for research facilities that track the use and care of veterinary research subjects. Pristima™ VM has been engineered to operate either stand alone or, more importantly, as an integrated solution with Xybion's core Pristima™ product that is in use in many of the world's premier pharmaceutical, contract research organization (CRO) and chemical research facilities that conduct product safety testing and research.
The integration of Pristima™ VM with the Pristima™ preclinical solution is a completely new way of thinking for vendors in this industry. This solution is filling a market void that the industry has been pressing vendors to address. Applications on the market today address only the animal management side of the business or the safety testing toxicology and pathology side of product research and development, leaving critical gaps in the flow of information for pharmaceutical, CRO or other research organizations. Xybion has now closed that gap and provided something that no other vendor has been able to, a conduit between the business, animal management and scientific aspects of research.
Pristima™ VM will be publicly debuted at the American Association for Laboratory Animal Science's National Meeting in Denver November 9-11, 2009 at Booth #506. To receive information about Pristima™ VM or Pristima™ visit http://www.xybion.com.
About Xybion Medical Systems
Xybion is the enterprise system partner of choice for life sciences product companies and research organizations worldwide. In addition to Pristima, Xybion provides professional services, consulting, training and validation activities to clients throughout the world. (http://xybion.com)
September 21, 2009 Cedar Knolls, NJ - Xybion Medical Systems Releases Pristima™ 6 with Integrated Colony Management
Robust enterprise application is a “game changer” for the preclinical medical research community
Xybion Medical Systems, a world leader in enterprise research solutions and the developer of Pristima™ the premier preclinical data management system on the market, is excited to announce the release of Pristima 6. This milestone release includes a host of improvements throughout the entire product suite and specifically introduces the Pristima Colony Management module to the toxicology community.
Pristima Colony Management fully integrates the toxicology laboratory teams with the animal husbandry unit, thus completing an electronic chain of custody and animal monitoring process that includes animal orders, animal shipments, non-study related health assessments and enforcing study readiness criteria before animals are assigned to any study. Pristima Colony Management also enables animals to be returned to the colony and assigned to a new study, building an individual animal’s history of diagnoses across time.
Dr. Pradip Banerjee, Xybion’s chief executive officer stated that “We are thrilled to build this unique and powerful functionality into Pristima. Until Pristima 6, there was no single solution on the market that could track an entire history of the animal’s experience. This is also a perfect example where Xybion worked with the client community to develop a set of requirements, and then developed and released it in record time.” Dr. Banerjee continued, “Pristima is the most flexible and feature-rich toxicology and pathology system on the market and the Colony module further extends its lead over competitive products. It is truly a game-changer for facilities that are seeking to improve their compliance and reduce the costs of managing the research process.”
Pristima 6 arrives at a time when streamlining the research environment and reducing the use of animals in research testing is of utmost importance to organizations. Earlier this year the United States, European Union, Japan and Canada signed a memorandum of cooperation seeking to reduce the number of animals used in regulatory health and safety assessments. “Xybion has had a long history of helping our customers to support the efficacious use of animals in research.” commented Carlos Frade, Vice President of Business Development for Xybion. “Pristima 6 crosses a new frontier in providing the management tools to support this effort.”
Pristima 6 is available directly from Xybion Medical Systems (www.xybion.com)
About Xybion Medical Systems – Since 1977, Xybion has been the enterprise system partner of choice for life science product companies and scientific research organizations worldwide. In addition to Pristima, Xybion provides professional services, consulting, training, and validation activities to clients around the world. (www.xybion.com)
September 8, 2009 - Cedar Knolls, NJ - Xybion Medical Systems Expands Pristima™ Software to Include Full Range of Vivarium Management Capabilities
August 11, 2009 - Cedar Knolls, NJ - Korea Institute of Toxicology Upgrades to Pristima
Xybion Medical Systems, a world leader in preclinical data management solutions and the developer of Pristima the premier preclinical solution on the market, is pleased to announce that Korea Institute of Toxicology (KIT) is upgrading to Pristima at its facilities in Daejeon and Jeongeup, South Korea.
Since 2002, KIT has been a Xybion client and has used Xybion's previous PATH/TOX SYSTEM suite as an integral business driver; using the system to plan, collect, manage and report all of its General Toxicology data. With this upgrade, KIT has expanded its software licenses to include the Pharmacy and Reproductive Toxicology modules so as to implement the full Pristima suite to cover all of its toxicology studies. With this system upgrade and expansion, KIT also chose to license Xybion's standard validation package to expedite the project and provide for a solid validation project.
Dr. Pradip Banerjee, Xybion's CEO, stated that 'this upgrade and expansion of deployed modules at KIT further exemplifies the advantages of a completely integrated system that has more built-in functionality and business intelligence than any other product on the market.'
The Daejeon and Jeongeup sites together comprise of over 500,000 square feet of facility space so KIT is the largest, most well-known GLP facility in South Korea and serves markets all over the world. With a vast experience in all study types, combined with highly automated procedures and reporting capabilities, KIT can define, perform and report client studies in record time and with the highest of quality. PATH/TOX SYSTEM and now Pristima, serve to capture and integrate all of the preclinical data at KIT while serving to enforce SOP's, prevent errors and summarize the results.
Myung-Sang Kwon (President) of Korea Toxicology Institute stated 'we are very anxious to start using the Pristima system since our evaluation process revealed that it will facilitate our most complex study designs. It seems that Pristima is designed specifically to take into consideration the most modern concepts in toxicology study design and KIT has always been at the forefront of the best scientific approaches.'
About Korea Institute of Toxicology
Korea Institute of Toxicology (KIT) is a world-class prestigious non-clinical contract research organization located in South Korea. KIT's GLP system has been certified by Korean and international regulatory authorities based on OECD and US FDA GLP criteria. Also, KIT is the first organization in Asia accredited by AAALAC International. KIT offers a full range of non-clinical research with high scientific standard and competitive pricing. (www.kitox.re.kr/eng/)
About Xybion Medical Systems - Xybion is the enterprise system partner of choice for life sciences product companies and research organizations worldwide. In addition to Pristima, Xybion provides professional services, consulting, training and validation activities to clients throughout the world. (www.xybion.com)
August 5, 2009 - Cedar Knolls, NJ - SK Life Sciences, Inc. Licenses Pristima
April 20, 2009 - FRANKFURT, Germany - NEW OFFICE IN GERMANY
Xybion Medical Systems, a world leader in preclinical data management solutions and the developer of Pristima™ the premier enterprise solution on the market, has opened a new sales and support office in Frankfurt, Germany. This office will strengthen Xybion’s European sales network and broaden local customer service capabilities.
Dr. Pradip Banerjee, CEO of Xybion Medical Systems explained: “It is quite obvious that our presence in Europe will benefit our clients here in the Eurozone. Frankfurt is a clear, central point from which we can easily reach out to our clients in Germany and all over Europe. Our local commercial presence will facilitate business communications and customer support throughout the European market.”
The Frankfurt office complements Xybion’s headquarters in Cedar Knolls, New Jersey in the United States and provides greater geographic coverage and access for its customers.
With Christoph Jeggle and Dr. Rainer Kossow, Xybion is providing two leading experts for the German-speaking and European region. Mr. Jeggle and Dr. Kossow have long and unique careers in IT support for preclinical studies and have fostered and managed many projects with Xybion in the past. Their wealth of experience includes process improvement, requirements analyses, system configuration, user training and all aspects of software validation.
“Our goal is to develop a strong pipeline of service offerings and expand our European market share, building on the recognition of the Pristima brand and product quality” said Carlos Frade, Vice President of Xybion. “Our greatest differentiator is our Pristima system, the most tightly integrated, comprehensive and robust solution available on the market today. By providing services around the product, we can truly provide the European customer base with a single vendor solution.”
The contact details for Xybion Medical Systems' new office are:
Xybion Medical Systems Corporation
Herriotstrasse 1
60528 Frankfurt
Phone: +49 (0) 69 6 77 33 456
Fax: +49 (0) 69 6 77 33 200
Xybion Medical Systems' Pristima system addresses all aspects of preclinical data acquisition, management and reporting. Xybion Medical Systems' product is used by the world's largest and most prestigious pharmaceutical, chemical and contract research companies in compound safety assessment. Xybion Medical Systems, headquartered in Cedar Knolls, NJ, is the primary operating arm of Xybion Corp., a life sciences research and development support firm, engaged in e-clinical, e-pre-clinical, e-research and discovery software and management services.
Mar. 16, 2009, Cedar Knolls, NJ – PATH/TOX SYSTEM™ is now Pristima™
Xybion Medical Systems Corp. announced that Pristima™ is the new brand name for its Next Generation PATH/TOX SYSTEM preclinical enterprise system. The new brand name is designed to help current and potential clients identify with the most comprehensive enterprise solution for preclinical research.
Dr. Pradip Banerjee, Xybion’s Chairman and CEO stated “The Pristima brand will help current and potential clients better distinguish the product name from the company name and distinguish the product name from the common “PTS” or “Next Gen” references used by many scientists. It is also important that clients be able to distinguish this product from our previous VMS and HP based versions. Pristima is a much more comprehensive system than any of the previous PATH/TOX SYSTEM versions and we feel a new Pristima brand helps clients to better identify this powerful platform that they use.”
Xybion officially launched the Pristima brand at the 48th Annual Society of Toxicology Meeting in Baltimore Maryland.
26 February 2009 - Xybion Medical Systems Corp. and Instech Solomon are joining to develop an interface between Pristima™ and ORCHESTA™
Instech Solomon and Xybion Medical Systems Corp. announced that they are joining to develop an interface between Instech Solomon's ORCHESTA™ lab animal infusion system and Pristima™, Xybion's laboratory information system for safety assessment.
The interface, to be delivered in the autumn of 2009, will enable Instech Solomon's patent pending ORCHESTA wireless infusion system to request and use current study-related information from Pristima to control flow rates and administered volume for up to 300 animals per study. Such an interface will yield reductions in labor costs and human error.
"Interfacing Pristima to ORCHESTA using real time communications eliminates manual transfer of data from one system to the other to drive an individual infusion" said Carlos Frade, Vice President of Xybion Medical Systems. "This seamless solution assures the accuracy of each animal's daily infusion volume as Pristima provides the most current data at the start of the infusion. The complexities associated with large infusion studies will be dramatically reduced with this interface."
Andy Jacobson, a co-owner of Instech Solomon stated that "we are excited to work with Xybion. The two technologies make for an elegant solution that immediately and robustly addresses an intensive operation for our clients. ORCHESTA is the first automated lab animal infusion system to integrate syringe pumps, wireless hardware and superior control and monitoring software. Integrating to Pristima further automates the entire infusion process."
Xybion Medical Systems' Pristima system addresses all aspects of preclinical data acquisition, management and reporting. Xybion Medical Systems' product is used by the world's largest and most prestigious pharmaceutical, chemical and contract research companies in compound safety assessment and to reduce the time involved in bringing a drug or chemical to market. Also providing software validation services to the industry, Xybion Medical Systems, headquartered in Cedar Knolls, NJ, is the primary operating arm of Xybion Corp., a life sciences research and development support firm, engaged in e-clinical, e-pre-clinical, e-research and discovery software and management services
Instech Solomon designs, develops and manufactures instruments for biomedical research. Instech Solomon's business comes from a range of products including infusion pump systems, implanted devices, and other devices routinely used in drug development and safety testing.
09 October 2008 - Carlos Frade Appointed Vice-President of Business Development
Xybion Medical Systems Corp. announced the appointment of Carlos Frade as Vice-President of Business Development, effective immediately. Mr. Frade will report to Dr. Pradip Banerjee, Chairman and Chief Executive Officer of Xybion.
“We are at an important juncture at Xybion as we focus on expanding our marketing and sales operations and look for new markets and new customers. In his new role, Carlos will be responsible for planning and executing our strategies in overall business development and product management with a special focus on creating and maintaining strong customer relationships,” said Dr. Banerjee.
Mr. Frade started at Xybion in 1988 as a computer analyst and most recently served as director of business development.
Mr. Frade’s appointment follows on the heels of the launch on September 30 of a full suite of developmental and reproductive toxicology functionality in Xybion’s PATH/TOX SYSTEM and a broader expansion of Xybion's marketing and sales capability.
Xybion Medical Systems Corp. is engaged in the development, maintenance and support of a software system that addresses all aspects of preclinical data acquisition, management and reporting. Xybion's product is a leader in this industry used by some of the largest and most prestigious pharmaceutical and chemical companies in the world to assess compound safety and to reduce the time involved in bringing a drug or chemical to market. Xybion also provides software validation services to the industry. Xybion Medical Systems, headquartered in Cedar Knolls, NJ, is the primary operating arm of Xybion Corp., a life sciences research and development support firm, engaged in e-clinical, e-pre-clinical, e-research and discovery software and management services
02 October 2008 - Berlin, Germany - Xybion Launches Full Repro Functionality in PATH/TOX SYSTEM®
At the annual Xybion User Group Meeting, Xybion Medical Systems announced the launch of a full suite of Developmental and Reproductive toxicology functions as part of its flagship PATH/TOX SYSTEM® data management system for safety assessment.
By extending the in-vivo and post-mortem areas of PATH/TOX SYSTEM to account for maternal, embryo-fetal and pup data assessment capabilities, Xybion allows its current client community to leverage the training, validation and infrastructure already in place for standard toxicology studies for rapid deployment of these new functions. New clients benefit from the ability to implement a single product that automatically supports all of its safety assessment requirements.
Specifically, PATH/TOX SYSTEM now supports common study types such as:
- Multi-generation – up to F3
- Fertility
- Embryo-fetal Development
- Pre- and Post-natal Development
- Behavioral
- Developmental Toxicity
- Developmental Neurotoxicity
- Juvenile Toxicology
Dr. Pradip Banerjee, CEO of Xybion Medical Systems, stated that “with this launch of the Repro module Xybion now offers a single data management system to acquire, manage and report data for every type of safety assessment study currently conducted at any facility in the world. In such a challenging environment as drug discovery, it is essential that clients be provided with comprehensive solutions that can be rapidly deployed to maximize both ROI and laboratory efficiency. PATH/TOX SYSTEM is the only solution designed from the ground up to be ‘One System,’ already fully integrated to support a wide variety of GLP and non-GLP study designs needing no further third-party tools, thus eliminating integration costs required by most other systems.”
Xybion's PATH/TOX SYSTEM is the most comprehensive pathology and toxicology data management system available today. It integrates numerous laboratory activities, including in-life toxicology, pharmacy, clinical pathology, reproductive toxicology and teratology, necropsy and histopathology. The System is protocol-driven, and is designed to promote compliance with regulatory data management requirements including full compliance with 21CFR part 11.
Xybion Medical Systems Corp. is engaged in the development, maintenance and support of a software system that addresses all aspects of preclinical data acquisition, management and reporting. Xybion's product is a leader in this industry used by some of the largest and most prestigious pharmaceutical and chemical companies in the world to assess compound safety and to reduce the time involved in bringing a drug or chemical to market. Xybion also provides software validation services to the industry. Xybion Medical Systems, headquartered in Cedar Knolls, NJ, is the primary operating arm of Xybion Corp., a lifesciences research and development support firm, engaged in R&D software and management services.
27 February 2008 - Xybion Medical Systems Acquired by Banerjee Group LLC
Xybion announced today that it has been acquired by Banerjee Group LLC, formed by Dr. Pradip K. Banerjee, a retired senior partner of Accenture.
“We are very excited about Banerjee Group’s acquisition of Xybion”, said Jennifer Feldmann, President of Xybion Medical Systems. “Dr. Banerjee’s background is a perfect fit for our company. His expertise in life sciences will help us to further expand and refine our product and service offerings for integrated drug development solutions.”
“I see a lot of opportunity at Xybion.” said Pradip Banerjee. “It’s reputation in the market, technical capabilities and the knowledge of its staff are all exceptional. The Next Generation PATH/TOX SYSTEM product line will provide the base for continued company growth for products and services, and I am looking forward to leading Xybion into customer centric new initiatives while continuing its tradition of quality and service.”
Dr. Banerjee is an entrepreneurial senior executive who brings over 25 years of in-depth experience in the global Life Sciences, Healthcare and Services industry in strategic management, business development, investments and new ventures creation. Dr. Banerjee was the Partner-in-Charge of the pharmaceutical Research & Development unit of Accenture where he created the R&D consulting unit and had grown it to become $100+ million worldwide business with projects focused on creating “Right Products to Market Faster” for most of the major pharmaceutical companies in the US, Europe and Japan. Dr. Banerjee is an operating partner of Tri-Artisan Capital, a private equity buy-out and a merchant banking firm. Most recently Dr. Banerjee was the President & CEO of Science Center in Philadelphia where he created a unique “commercialization Engine” for early stage life sciences companies through hands on management and venture capital funding to accelerate growth of these companies. Previously he held various R&D management leadership positions at SmithKline and Abbott. He has been involved with various early stage entrepreneurial companies.
Dr. Banerjee is a Senior Fellow at the Wharton School of Business of the University of Pennsylvania and a Visiting Professor at Rutgers University where he teaches life sciences product development and business management. He holds a PhD in Pharmacy from University of Wisconsin and an MBA from the Wharton School of Business.
“The sale to Banerjee Group LLC returns Xybion to active ownership, and strengthens its core commitment to provide a comprehensive, single-system solution using the latest in technological innovations, to work as partners with our customers to identify and implement timely, high-quality, user-friendly products.” Said Ms. Feldmann.
Xybion Medical System’s core management team remains in place, and there are no changes planned to development plans which are currently in place. Xybion Medical Systems develops and supports PATH/TOX SYSTEM, which is a software system that addresses all aspects of preclinical data acquisition, management and reporting. Xybion's products are the leaders in this industry and are used by some of the largest and most prestigious pharmaceutical and chemical companies in the world to assess compound safety and to reduce the time involved in bringing a drug or chemical to market. Xybion Medical Systems is headquartered in Cedar Knolls, New Jersey. For further company information, visit www.xybion.com.
19 October 2006 – Stelex and Xybion Announce Partnership to Provide Turnkey Services
Stelex, a firm providing enterprise-wide compliance solutions to the regulated industries and Xybion Medical Systems Corporation (Xybion), the developer and supplier of PATH/TOX SYSTEM™, a state-of-the-art comprehensive preclinical data management system, today announced the signing of a strategic alliance and services agreement.
The PATH/TOX SYSTEM is a single solution that addresses all aspects of preclinical data acquisition, management and reporting. It is in use in 9 different countries throughout North America, Europe and Asia
“Stelex’ 20 years of experience and regulatory know-how in the areas of computer system implementation and validation, combined with Xybion’s 28 years of experience providing standard and custom enterprise data management solutions, is a win-win situation for both companies but more importantly for clients who are looking for a turnkey solution,” said Tony Kashani, President of Stelex.
“The ability to provide clients a single source for critical path products and services is a compelling marketing advantage; providing turnkey solutions through an alliance between industry leaders ensures that our clients receive the best and most cost effective solution available,” said David M. Neglia President of Xybion Medical Systems Corporation.
About Xybion Medical Systems Corporation
Since 1977, Xybion has provided software and services to the pharmaceutical and chemical research communities. Our success is evidenced by the continuous expansion of our client base and by the evolution of our products and services to meet the growing needs of this community. With over 50 active client sites, PATH/TOX SYSTEM enjoys a large, diverse client base ranging from the largest pharmaceutical companies in the world to smaller biotechnology and contract research organizations. Visit Xybion’s web site for more information: www.xybion.com
About Stelex
Stelex is a consulting firm providing enterprise-wide compliance solutions to regulated industries in the Pharmaceutical, Medical Device, Diagnostic and Biotechnology sectors for over 20 years. The firm delivers a comprehensive suite of Validation, Technology, Regulatory and Business solutions. Learn more about Stelex at www.stelex.com.
Stelex is a subsidiary of Vital Signs, Inc. (NASDAQ: VITL). Vital Signs, Inc. and its subsidiaries design, manufacture and market primarily single-use medical products for the anesthesia, respiratory/critical care and sleep/ventilation markets. Vital Signs is ISO 13485 certified and has CE Mark approval for its products.
All statements in this press release other than historical statements constitute Forward Looking Statements under the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements as a result of a variety of factors, including but not limited to the changes in regulatory requirements in the United States and elsewhere, timing and effectiveness of changes to marketing and sales plans, programs and strategies; market conditions; customer response; technological change; and competition and other factors referred to by Vital Signs in its Annual Report on Form 10-K for the year ended September 30, 2005 and other reports filed with the Securities and Exchange Commission.
12 September 2006 – Biotechnology Company Licenses PATH/TOX SYSTEM™
Xybion Medical Systems Corporation (Xybion), the developer and supplier of PATH/TOX SYSTEM™, a state-of-the-art comprehensive preclinical data management system, announced today that one of the world’s leading international biotechnology companies has selected Xybion to provide a turnkey solution for the collection, management and reporting of safety assessment data related to their human therapeutics research activities being conducted throughout the United States. Respecting our client’s confidentiality requirements, the company’s name is not being disclosed.
“We are delighted that a Fortune 500 company, ranked among the world’s largest pharmaceutical companies, has determined that PATH/TOX SYSTEM is the premier data management solution available today,” said David M. Neglia, President of Xybion. “The award of this highly competitive contract represents a significant achievement and further strengthens Xybion’s position as the leading provider of pre-clinical enterprise solutions."
PATH/TOX SYSTEM is a single solution that addresses all aspects of preclinical data acquisition, management and reporting. It is in use in 9 different countries throughout North America, Europe and Asia. Clients have the flexibility to license those components and options needed to support their study protocols and processes providing a client-centric, custom solution. Xybion’s products and services are industry leaders and are used by the world’s largest and most prestigious, as well as many smaller companies, in the biotechnology, pharmaceutical, chemical and contract research industries to assess compound safety while reducing post-discovery research costs and time to market.
26 August 2006 – Orion Corporation Licenses PATH/TOX SYSTEM™
Xybion Medical Systems Corporation (Xybion), a developer and supplier of comprehensive preclinical data management systems, including its PATH/TOX SYSTEM™ Next Generation, announced today that Orion Corporation (Orion) has licensed PATH/TOX SYSTEM for the collection, management and reporting of data related to their pharmaceutical research and development activities being conducted at their research sites in Finland.
“We are pleased that Orion has decided to license and deploy the newest version of PATH/TOX SYSTEM to replace the OpenVMS legacy version currently in use at Orion’s facilities”, said David M. Neglia, President of Xybion. “It is rewarding to see that our ongoing investment in development and our commitment to quality products and services is recognized by the market making Xybion the premier preclinical data management solution partner.”
PATH/TOX SYSTEM is a single solution that addresses all aspects of preclinical data acquisition, management and reporting. It is in use in 9 different countries throughout North America, Europe and Asia. Clients have the flexibility to license those components and options needed to support their study protocols and processes providing a client-centric custom solution. Xybion’s products are industry leaders and are used by the world’s largest and most prestigious pharmaceutical, chemical and contract research companies to assess compound safety while reducing the time to market.
30 March 2006 – Bayer Licenses Path/Tox System
Xybion Medical Systems Corporation (Xybion), a developer and supplier of comprehensive preclinical data management systems, including its PATH/TOX SYSTEM™ Next Generation, announced today that Bayer HealthCare AG and Bayer CropScience AG, subgroups of Bayer AG have licensed PATH/TOX SYSTEM for collection, management and reporting of data related to their pharmaceutical and agrochemical safety assessment research being conducted at their development sites in Germany, France and the U.S.
“Bayer HealthCare AG and Bayer CropScience AG carried out a thorough market analysis in close cooperation on preclinical data management systems.” Gernot Goeller, Bayer HealthCare Project Lead said. “Both parties came to the same conclusion. The results convinced both our scientists and our lab technicians that the new PATH/TOX SYSTEM from Xybion Medical System will not only meet our needs but will also provide us with a range of important functionalities that where not available up to now. In addition, we look forward to having one single system in place world wide covering the needs for the safety assessment of new pharmaceuticals as well as agricultural products. A system covering the whole toxicology study process from test substance receipt to pathology”
“Bayer’s decision to license and deploy PATH/TOX SYSTEM world-wide demonstrates the marketplace’s continuing confidence in the high quality solutions provided by Xybion and in its world class customer service”, said David M. Neglia, President of Xybion. “We are delighted to see that our investment in development and our attention to quality is recognized by the market and considers Xybion a premier preclinical data management solution partner. The award of this contract contributed to Xybion’s most successful year; a total of eight new laboratories representing approximately 750 licensed users were added to Xybion’s user community.”
22 December 2005 – A message from the President
As we approach the end of the year, I would like to take this opportunity to wish all of you and your families a peaceful holiday season along with a happy, healthy and prosperous year in 2006. 2005 was filled with excitement, hard work and success at Xybion; we released the Animal Room, Necropsy Room and Histopathology areas; we are nearly complete with the new Pharmacy area and are well under way with our expanded Clinical Pathology area.
So far, clients representing 19 sites and over 2,000 users, have entered into agreements to upgrade to the new system and are in various stages of the validation process. We expect a continued increase in the number of newly licensed sites and upgrades in 2006. The completion of the remaining system areas along with the capabilities for enhanced statistics and reproduction studies will make 2006 an important year. We appreciate and depend on our client community’s involvement in the design, development and beta testing of the system.
Some vendor companies are taking new initiatives to listen to their clients – at Xybion, listening to the clients has always been integral to our mission. Replacing Version 4.2.2 functionality and adding a tremendous amount of new functionality in Next Generation PATH/TOX SYSTEM has been a challenge. As we near completion of the remaining areas, I would like to thank you for your ideas, your support, and your patience. We are confident that PATH/TOX SYSTEM will meet or exceed your expectations, and encourage you to begin your implementation plans if you have not already done so.
Finally, I hope that you will join me in thanking my Xybion co-workers for their extraordinary efforts this year. They have put in long hours in work and travel to design, develop and deploy the most innovative and flexible data management system that has come along in this industry in years. We believe that 2006 will be another exciting and successful year for Xybion; we are pleased to share our success with you and look forward to continuing our close working relationship. Happy Holidays and Happy New Year!
22 December 2005 – Pathology Data Management Released
Xybion is pleased to announce the formal release of the Pathology area of PATH/TOX SYSTEM Next Generation. This is the completion of a long project of designing developing and testing the most user-friendly, most efficient, most modern pathology data management system on the market today. Designed with the help of pathologists from our client facilities, the system combines all of the functionality and navigation keys together with a new, modern user interface running on Microsoft Windows.
5 October 2005 – Xybion User Group Meeting
At its annual user's group meeting in Boston, Massachusetts Xybion greeted an audience of over 70 client attendees with news that three new top 20 pharmaceutical companies had begun or recently completed the licensing of PATH/TOX SYSTEM Next Generation. This marketing success will add 8 new facilities and approximately 750 new users to Xybion's growing community across North America, Europe and Asia. The three-day meeting was extraordinarily busy and productive with clients participating in strategic planning with Xybion and providing creative feed back to Xybion's demonstrations of upcoming products.
29 September 2005 – Necropsy Room Data Management Released
Xybion is proud to a release the Necropsy functions of PATH/TOX SYSTEM Next Generation. This release is the is the first step of re-designing the post-mortem data management functions of PATH/TOX SYSTEM such that there is a common, user friendly approach between the necropsy measurements and the pathology measurements.
1 June 2005 – Animal Room Data Management Released
Today, Xybion released the Animal Room and Study Tools functions of PATH/TOX SYSTEM Next Generation. The release of these components of the system now ties together with the previous release of the System Management and Study Management functions to enable the user to capture, manage and report animal room, in-vivo data.